CCHI Formulary Reference

CCHI Drug Formulary: Complete Guide for Saudi Healthcare Providers

The Council of Cooperative Health Insurance (CCHI) mandates that all licensed private health insurers in Saudi Arabia cover medications listed on the Saudi Drug Formulary (SDF). Understanding the formulary's structure, tier system, and prior authorization requirements is essential for Saudi pharmacy and RCM teams — formulary non-compliance is one of the most common and preventable causes of medication claim rejections on NPHIES.

1. What Is the CCHI Drug Formulary?

The Saudi Drug Formulary (SDF) is the official list of medications approved for reimbursement by CCHI-licensed health insurers. Maintained by CCHI in coordination with the Saudi FDA, the formulary is updated periodically and applies to all private sector healthcare facilities and pharmacies. Every medication dispensed to an insured patient must be either (a) listed on the formulary or (b) approved through a non-formulary exception process before being billed to insurance.

The 2024 SDF contains over 3,200 drug entries across branded and generic versions. CCHI regularly adds new medications (especially biologics and oncology agents) and removes drugs that have been superseded by more cost-effective alternatives. Keeping your pharmacy formulary database current is a critical RCM function.

2. Formulary Tiers Explained

TierNameCost SharingCoverageNotes
Tier 1Generic / Multi-SourceLowest co-pay80–100% covered by most plansPreferred first-line option; no prior auth for most
Tier 2Preferred BrandModerate co-pay70–90% coveredSingle-source branded drugs with generic equivalents
Tier 3Non-Preferred BrandHigher co-pay50–80% coveredMay require step therapy proof before approval
Tier 4Specialty DrugsHighest co-payVaries; often 50–70%Biologics, oncologics, high-cost injectables; PA almost always required
Non-FormularyNot on SDFPatient paysNot covered without PA exceptionException request required; rarely approved without compelling clinical justification

3. Prior Authorization for Formulary Drugs

Even formulary drugs often require prior authorization when:

1

Drug is Tier 3 or Tier 4

Higher-tier drugs require PA because CCHI payers want to confirm that lower-tier alternatives were considered first. The PA request must document why the Tier 1/2 alternative was inadequate (e.g., allergy, therapeutic failure, contraindication).

2

Quantity Exceeds Standard Limits

Each formulary drug has a defined daily dose (DDD) and a maximum quantity per dispensing period. Claims that exceed the standard quantity limits — even for formulary drugs — are automatically rejected. PA is required to approve extended quantities for chronic conditions.

3

Off-Label Use

When a formulary drug is prescribed for an indication not listed in the SDF, prior authorization is always required. The PA request must include clinical evidence supporting the off-label use.

4. Step Therapy and Quantity Limits

Step therapy (also called "fail-first" or "therapeutic substitution") requires that patients try a lower-cost or lower-tier medication before a higher-tier drug is approved. Example: A patient prescribed Adalimumab (Humira, Tier 4) for rheumatoid arthritis must demonstrate (in the medical record) that they tried at least one conventional DMARD (e.g., Methotrexate) and it failed or was contraindicated.

Common Step Therapy Requirements by Drug Class

Drug ClassFirst-Line RequiredCommon Biologic/Specialty
TNF inhibitors (RA/IBD)Methotrexate, Sulfasalazine, or LeflunomideAdalimumab, Etanercept
PCSK9 inhibitors (dyslipidemia)High-dose statin ≥ 3 monthsEvolocumab, Alirocumab
GLP-1 agonists (type 2 DM)Metformin + 2nd agent ≥ 3 monthsSemaglutide, Liraglutide
JAK inhibitors (RA)Conventional DMARD failure + TNF inhibitor failureBaricitinib, Tofacitinib

5. Common Formulary Rejection Reasons

Non-Formulary Drug Billed Without Exception

The dispensed drug is not on the SDF and no non-formulary exception was approved before dispensing. Solution: always verify formulary status at the time of prescribing, not after dispensing.

Quantity Limit Exceeded

The quantity dispensed exceeds the formulary's defined limit without a PA approval for extended quantity. Solution: obtain PA for extended supply before dispensing, especially for chronic disease management.

Step Therapy Not Documented

A Tier 3/4 drug was requested without documenting that required first-line drugs were tried and failed. Solution: CDI review of the chart to ensure therapeutic failure is clearly documented before PA submission.

Prior Authorization Expired

The PA was valid when first dispensed but has since expired. Renewal PA was not obtained. Solution: implement PA expiry tracking in pharmacy systems.

Drug-Diagnosis Mismatch

The prescribed drug is not indicated for the billed ICD-10-AM diagnosis code. This is automatically flagged by NPHIES. Solution: confirm that the prescription's indication matches the patient's documented diagnosis.

6. Optimizing Formulary RCM with RCMHelper

RCMHelper supports formulary-related RCM through its PreAuth CDI Analyzer, which flags documentation gaps that would cause formulary prior authorization denials. Before submitting a PA for a Tier 3/4 drug or a step-therapy-controlled medication, the CDI Analyzer reviews the clinical note and identifies whether: (a) therapeutic failure of first-line agents is documented, (b) contraindications to lower-tier drugs are stated, (c) the diagnosis in the chart matches the drug's indication on the SDF, and (d) quantity justification for extended supply is documented.

For non-formulary exception requests, RCMHelper generates structured PA request documentation using the clinical information in the patient record — reducing the time physicians spend writing PA justification letters and increasing the approval rate by ensuring all required clinical evidence is included.

7. FAQ

What is the Saudi Drug Formulary (SDF)?

The Saudi Drug Formulary (SDF) is the official list of medications approved for reimbursement by CCHI-licensed health insurers. Maintained by CCHI and the Saudi FDA, it covers thousands of branded and generic drugs organized into coverage tiers.

Does every medication require prior authorization?

No. Tier 1 (generic) and most Tier 2 (preferred brand) drugs do not require prior authorization for standard quantities and approved indications. Prior authorization is required for Tier 3/4 drugs, specialty medications, extended quantities, and off-label use.

What happens if we dispense a non-formulary drug without an exception?

The claim will be automatically rejected by the payer's NPHIES system. The patient may be billed directly, which creates patient satisfaction and compliance issues. Always verify formulary status before dispensing, or obtain a non-formulary exception approval in advance.

How does step therapy documentation affect RCM?

If step therapy documentation is missing from the chart, the PA for the higher-tier drug will be denied — even if the physician clinically decided the lower-tier drug was inappropriate. CDI review before PA submission ensures all step therapy decisions are documented in the record.

Prevent formulary rejections before they happen.

RCMHelper's CDI Analyzer checks documentation completeness for every prior authorization request. Start free.